Atika Capital Management LLC Has $29.22 Million Stock Holdings in Inspire Medical Systems, Inc. (NYSE:INSP)

Atika Capital Management LLC lessened its holdings in Inspire Medical Systems, Inc. (NYSE:INSP) by 1.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 157,600 shares of the company’s stock after selling 2,400 shares during the quarter. Inspire Medical Systems makes up approximately 3.1% of Atika Capital Management LLC’s holdings, making the stock its 5th biggest holding. Atika Capital Management LLC’s holdings in Inspire Medical Systems were worth $29,216,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Mutual of America Capital Management LLC lifted its stake in Inspire Medical Systems by 1.2% in the fourth quarter. Mutual of America Capital Management LLC now owns 4,540 shares of the company’s stock valued at $842,000 after buying an additional 55 shares during the period. Wealth Enhancement Advisory Services LLC increased its stake in shares of Inspire Medical Systems by 1.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 7,879 shares of the company’s stock valued at $1,461,000 after acquiring an additional 79 shares during the last quarter. Xponance Inc. raised its position in shares of Inspire Medical Systems by 2.2% in the 4th quarter. Xponance Inc. now owns 3,824 shares of the company’s stock valued at $709,000 after acquiring an additional 82 shares during the period. Harbour Investments Inc. boosted its stake in Inspire Medical Systems by 101.0% during the 4th quarter. Harbour Investments Inc. now owns 197 shares of the company’s stock worth $37,000 after acquiring an additional 99 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its holdings in Inspire Medical Systems by 37.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 368 shares of the company’s stock valued at $68,000 after purchasing an additional 100 shares during the period. Institutional investors and hedge funds own 94.91% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on INSP. Truist Financial reduced their price target on shares of Inspire Medical Systems from $250.00 to $235.00 and set a “buy” rating on the stock in a research report on Tuesday, February 11th. Royal Bank of Canada reiterated an “outperform” rating and set a $260.00 target price on shares of Inspire Medical Systems in a report on Tuesday, February 11th. Wells Fargo & Company lowered their price target on Inspire Medical Systems from $198.00 to $195.00 and set an “equal weight” rating for the company in a report on Tuesday, February 11th. Stifel Nicolaus cut their price objective on Inspire Medical Systems from $200.00 to $190.00 and set a “hold” rating on the stock in a report on Tuesday, January 21st. Finally, KeyCorp reissued an “overweight” rating and set a $234.00 target price (down from $236.00) on shares of Inspire Medical Systems in a research note on Friday, January 24th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $226.70.

Inspire Medical Systems Stock Down 5.3 %

Shares of INSP opened at $141.49 on Friday. Inspire Medical Systems, Inc. has a twelve month low of $123.00 and a twelve month high of $257.40. The stock has a market capitalization of $4.21 billion, a P/E ratio of 81.78, a P/E/G ratio of 2.86 and a beta of 1.39. The company has a 50 day moving average of $175.94 and a 200-day moving average of $188.21.

Inspire Medical Systems (NYSE:INSP) last announced its earnings results on Monday, February 10th. The company reported $1.15 EPS for the quarter, topping the consensus estimate of $0.74 by $0.41. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. On average, sell-side analysts anticipate that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current fiscal year.

Insider Activity

In related news, CTO John Rondoni sold 583 shares of the stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $170.49, for a total transaction of $99,395.67. Following the completion of the transaction, the chief technology officer now directly owns 10,424 shares of the company’s stock, valued at approximately $1,777,187.76. This represents a 5.30 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Randy Ban sold 25,584 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $183.50, for a total value of $4,694,664.00. Following the completion of the transaction, the insider now owns 7,259 shares of the company’s stock, valued at approximately $1,332,026.50. This represents a 77.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 26,225 shares of company stock worth $4,806,530 in the last quarter. Corporate insiders own 4.10% of the company’s stock.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.